Tag:
Xalkori
Latest Headlines
Latest Headlines
E.U. panel recommends Inlyta for adults with kidney cancer
E.U. regulators have recommended Pfizer's kidney cancer drug Inlyta be approved for use in patients who don't respond to other medications.
Pfizer's targeted drug knocks out child cancers in small study
Some of the biggest headlines coming out of the massive ASCO abstract release aren't focused on a promising experimental treatment. They're about Pfizer's recently approved treatment Xalkori.
Pfizer's targeted drug knocks out child cancers in small study
Xalkori was tested in children with rare cancers, and its success illustrates how targeted drugs can progress beyond their initial uses.
ASCO data to shine new light on Pfizer, Roche, J&J drugs
Cancer drug aficionados, rejoice. A slew of new studies goes public later today, as drugmakers gear up for next month's American Society of Clinical Oncology meeting.
Cancer drug experts brace for ASCO abstract dump tonight
ASCO is releasing a mountain of data on cancer studies, and some of the biggest names in the business will be angling for star billing on some closely watched therapies.
Support seen for U.S. plan to speed nods for 'breakthrough' drugs
This year the agency and U.S. lawmakers appear to be supportive of a plan that would help pharma groups race to the market with breakthrough drugs.
Top 10 late-stage cancer drugs in 2012
Thousands of experimental meds are winding their way through various stages of clinical trials today, and the largest category among the contenders is cancer drugs.
DNA sequencing exposes new uses for Pfizer targeted cancer drugs
As pharma companies expand their use of DNA sequencing for drug R&D, researchers have uncovered some potential new targets for existing cancer drugs that are likely to spur further use of
UPDATED: Pfizer nabs FDA nod for another targeted cancer drug
The FDA has stamped an approval on Pfizer's ( $PFE ) new kidney cancer drug axitinib, which the drug giant plans to market as Inlyta. And the approval marks another win on the targeted cancer drug
Pfizer targets miniblockbuster prospects as Lipitor patent expires
Pfizer ( $PFE ) has been gearing up for the expiration of Lipitor's patent for years, and with the big day finally upon us, analysts and industry watchers are weighing in on the R&D course that the
